ONCT / Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q4 2021 Results - Earnings Call Transcript

Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Salim Yazji - CMO James B more_horizontal

Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q1 2023 Results Conference Call May 4, 2023 5:00 PM ET Company Participants Salim Yazji - CMO James Breitm more_horizontal

Oncternal (ONCT) closes the development program for zilovertamab to extend its cash runway into 2025. Shares are down on the same. more_horizontal

Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q4 2022 Earnings Conference Call March 9, 2023 5:00 PM ET Company Participants James Breitmeyer - Presiden more_horizontal

As ONCT's MCL Phase 2 study continues to mature, the data also continues to improve.  In fact, the data now looks outstanding. Thus, I believe that t more_horizontal

Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q3 2022 Earnings Conference Call November 3, 2022 5:00 PM ET Company Participants Rich Vincent - Chief Fin more_horizontal

Today, we are circling back on Oncternal Therapeutics, Inc. for the first time since last October. Despite advancing its pipeline and strong analyst s more_horizontal

Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q2 2022 Earnings Conference Call August 9, 2022 5:00 PM ET Company Participants Richard Vincent - Chief Fi more_horizontal